Iron chelators and iron toxicity

Alcohol

Volumn 30, Issue 2, 2003, Pages 151-158

  Brittenham, Gary M ^a  

^a Columbia Univ Coll of Phys/Surgs ^*  (United States)

Author keywords

Chelator; Deferiprone; Deferoxamine; Desferrithiocins; HBED; ICL670A; Iron; Oxidative injury

Indexed keywords

4' HYDROXYDESAZANORDESFERRITHIOCIN; 4,5 DIHYDRO 2 (2,4 DIHYDROXYPHENYL) 4 THIAZOLE CARBOXYLIC ACID; BIDENTATE HYDROXYPYRIDIN 4 ONE; CARBOXYLIC ACID DERIVATIVE; DEFERASIROX; DEFERIPRONE; DEFERRIFERRITHIOCIN; IRON CHELATE; N,N' BIS(2 HYDROXYBENZYL)ETHYLENEDIAMINE N,N' DIACETIC ACID; PHENOL DERIVATIVE; TRIAZOLE DERIVATIVE; UNCLASSIFIED DRUG;

ALCOHOL LIVER DISEASE; CONFERENCE PAPER; EXTRACELLULAR MATRIX; HUMAN; IRON CHELATION; IRON OVERLOAD; LIVER CELL; LIVER FIBROSIS; LIVER INJURY; LIVER TOXICITY; MACROPHAGE; OXIDATIVE STRESS; SIGNAL TRANSDUCTION;

EID: 0042384674     PISSN: 07418329     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0741-8329(03)00101-0     Document Type: Conference Paper

References (84)

1. Adams P.C. Iron overload in viral and alcoholic liver disease. J Hepatol. 28:1998;19-20.
2. Adams P.C. Is there a threshold of hepatic iron concentration that leads to cirrhosis in C282Y hemochromatosis? Am J Gastroenterol. 96:2001;567-569.
3. Aisen P., Enns C., Wessling-Resnick M. Chemistry and biology of eukaryotic iron metabolism. Int J Biochem Cell Biol. 33:2001;940-959.
4. Angelucci E., Muretto P., Nicolucci A., Baronciani D., Erer B., Gaziev J., Ripalti M., Sodani P., Tomassoni S., Visani G., Lucarelli G. Effects of iron overload and hepatitis C virus positivity in determining progression of liver fibrosis in thalassemia following bone marrow transplantation. Blood. 100:2002;17-21.
5. Baker E., Wong A., Peter H., Jacobs A. Desferrithiocin is an effective iron chelator in vivo and in vitro but ferrithiocin is toxic. Br J Haematol. 81:1992;424-431.
6. Berdoukas V., Bentley P., Frost H., Schnebli H.P. Toxicity of oral iron chelator L1. Lancet. 341:1993;1088.
7. Bergeron R.J., Liu C.Z., McManis J.S., Xia M.X., Algee S.E., Wiegand J. The desferrithiocin pharmacophore. J Med Chem. 37:1994a;1411-1417.
8. Bergeron R.J., McManis J.S., Wiegand J., Weimar W.R., Brittenham G.M. A search for clinically effective iron chelators. Bergeron R., Badman D., Brittenham G. Iron Chelators: New Development Strategies. 2000;Saratoga Publishers, Ponte Vedra, FL.
9. Bergeron R.J., Wiegand J., Brittenham G.M. HBED: a potential alternative to deferoxamine for iron-chelating therapy. Blood. 91:1998;1446-1452.
10. Bergeron R.J., Wiegand J., Brittenham G.M. HBED: the continuing development of a potential alternative to deferoxamine for iron-chelating therapy. Blood. 93:1999a;370-375.
11. Bergeron R.J., Wiegand J., Brittenham G.M. HBED ligand: preclinical studies of a potential alternative to deferoxamine for treatment of chronic iron overload and acute iron poisoning. Blood. 99:2002;3019-3026.
12. Bergeron R.J., Wiegand J., Dionis J.B., Egli-Karmakka M., Frei J., Huxley-Tencer A., Peter H.H. Evaluation of desferrithiocin and its synthetic analogues as orally effective iron chelators. J Med Chem. 34:1991;2072-2078.
13. Bergeron R.J., Wiegand J., McManis J.S., McCosar B.H., Weimar W.R., Brittenham G.M., Smith R.E. Effects of C-4 stereochemistry and C-4′ hydroxylation on the iron clearing efficiency and toxicity of desferrithiocin analogues. J Med Chem. 42:1999b;2432-2440.
14. Bergeron R.J., Wiegand J., Weimar W.R., Vinson J.R., Bussenius J., Yao G.W., McManis J.S. Desazadesmethyldesferrithiocin analogues as orally effective iron chelators. J Med Chem. 42:1999c;95-108.
15. Bergeron R.J., Wollenweber M., Wiegand J. An investigation of desferrithiocin metabolism. J Med Chem. 37:1994b;2889-2895.
16. Bickel H., Hall G.E., Keller-Schierlein W., Prelog V., Vischer E., Wettstein A. Metabolic products of actinomycetes XXVII. Constitutional formula of ferrioxamine B . Helv Chim Acta. 43:1960;2129-2138.
17. Borgna-Pignatti C., Rugolotto S., De Stefano P., Piga A., Di Gregorio F., Gamberini M.R., Sabato V., Melevendi C., Cappellini M.D., Verlato G. Survival and disease complications in thalassemia major. Ann N Y Acad Sci. 850:1998;227-231.
18. Brittenham G.M. Disorders of iron metabolism: iron deficiency and overload. Hoffman B.E., Shattil S.J., Furie B., Cohen H.J., Silberstein L.E., McGave P. Hematology: Basic Principles and Practice. 2000;397-428 Churchill Livingstone, New York.
19. Brittenham G.M., Griffith P.M., Nienhuis A.W., McLaren C.E., Young N.S., Tucker E.E., Allen C.J., Farrell D.E., Harris J.W. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. N Engl J Med. 331:1994;567-573.
20. Chapman R.W., Morgan M.Y., Laulicht M., Hoffbrand A.V., Sherlock S. Hepatic iron stores and markers of iron overload in alcoholics and patients with idiopathic hemochromatosis. Dig Dis Sci. 27:1982;909-916.
21. Cohen A.R., Galanello R., Piga A., Dipalma A., Vullo C., Tricta F. Safety profile of the oral iron chelator deferiprone: a multicentre study. Br J Haematol. 108:2000;305-312.
22. Conrad M.E., Barton J.C. Anemia and iron kinetics in alcoholism. Semin Hematol. 17:1980;149-163.
23. Conte D., Corsetti M., Colli A., Bardella M.T., Cocciolo M., Fraquelli A.M. Iron-related indexes in chronic alcoholics. Effect of alcohol withdrawal. Ital J Gastroenterol Hepatol. 30:1998;534-538.
24. Courselaud B., Pigeon C., Inoue Y., Inoue J., Gonzalez F.J., Leroyer P., Gilot D., Boudjema K., Guguen-Guillouzo C., Brissot P., Loreal O., Ilyin G. C/EBPalpha regulates hepatic transcription of hepcidin, an antimicrobial peptide and regulator of iron metabolism. Cross-talk between C/EBP pathway and iron metabolism. J Biol Chem. 277:2002;41163-41170.
25. Cragg L., Hebbel R.P., Miller W., Solovey A., Selby S., Enright H. The iron chelator L1 potentiates oxidative DNA damage in iron-loaded liver cells. Blood. 92:1998;632-638.
26. Darnis F., Mosse A., Breaute C., Delorme M.L. [Present aspects of the treatment of hemochromatosis (apropos of 100 observations)]. Ann Med Interne (Paris). 122:1971;1193-1210.
27. Davis B.A., Porter J.B. Long-term outcome of continuous 24-hour deferoxamine infusion via indwelling intravenous catheters in high-risk beta-thalassemia. Blood. 95:2000;1229-1236.
28. De Feo T.M., Fargion S., Duca L., Cesana B.M., Boncinelli L., Lozza P., Cappellini M.D., Fiorelli G. Non-transferrin-bound iron in alcohol abusers. Alcohol Clin Exp Res. 25:2001;1494-1499.
29. Dean R.T., Nicholson P. The action of nine chelators on iron-dependent radical damage. Free Radic Res. 20:1994;83-101.
30. Delanghe J.R., Langlois M.R. Haptoglobin polymorphism and body iron stores. Clin Chem Lab Med. 40:2002;212-216.
31. Deugnier Y., Loréal O., Turlin B., Guyader D., Jouanolle H., Moirand R., Jacquelinet C., Brissot P. Liver pathology in genetic hemochromatosis: a review of 135 homozygous cases and their bioclinical correlations. Gastroenterology. 102:1992;2050-2059.
32. Duane P., Raja K.B., Simpson R.J., Peters T.J. Intestinal iron absorption in chronic alcoholics. Alcohol Alcohol. 27:1992;539-544.
33. Fargion S., Fracanzani A.L., Rossini A., Borzio M., Riggio O., Belloni G., Bissoli F., Ceriani R., Ballare M., Massari M., Trischitta C., Fiore P., Orlandi A., Morini L., Mattioli M., Oldani S., Cesana B., Fiorelli G. Iron reduction and sustained response to interferon-alpha therapy in patients with chronic hepatitis C: results of an Italian multicenter randomized study. Am J Gastroenterol. 97:2002;1204-1210.
34. Fleming R.E., Migas M.C., Holden C.C., Waheed A., Britton R.S., Tomatsu S., Bacon B.R., Sly W.S. Transferrin receptor 2: continued expression in mouse liver in the face of iron overload and in hereditary hemochromatosis. Proc Natl Acad Sci U S A. 97:2000;2214-2219.
35. Fletcher L.M., Halliday J.W., Powell L.W. Interrelationships of alcohol and iron in liver disease with particular reference to the iron-binding proteins, ferritin and transferrin. J Gastroenterol Hepatol. 14:1999;202-214.
36. Fontana R.J., Israel J., Le Clair P., Banner B.F., Tortorelli K., Grace N., Levine R.A., Fiarman G., Thiim M., Tavill A.S., Bonkovsky H.L. Iron reduction before and during interferon therapy of chronic hepatitis C: results of a multicenter, randomized, controlled trial. Hepatology. 31:2000;730-736.
37. Ganne-Carrié N., Christidis C., Chastang C., Ziol M., Chapel F., Imbert-Bismut F., Trinchet J.-C., Guettier C., Beaugrand M. Liver iron is predictive of death in alcoholic cirrhosis: a multivariate study of 229 consecutive patients with alcoholic and/or hepatitis C virus cirrhosis - a prospective follow up study. Gut. 46:2000;277-282.
38. Grace N.D., Greenberg M.S. Phlebotomy in the treatment of iron overload: a controlled trial (a preliminary report). Gastroenterology. 60:1971;744.
39. Grady R.W., Salbe A.D., Hilgartner M.W., Giardina P.J. Results from a phase I clinical trial of HBED. Adv Exp Med Biol. 356:1994;351-359.
40. Grove J., Daly A.K., Burt A.D., Guzail M., James O.F., Bassendine M.F., Day C.P. Heterozygotes for HFE mutations have no increased risk of advanced alcoholic liver disease. Gut. 43:1998;262-266.
41. Halliwell B. Iron, oxidative damage, and chelating agents. Bergeron R.J., Brittenham G.M. Development of Iron Chelators for Clinical Use. 1994;33-56 CRC Press, Boca Raton.
42. Hershko C., Grady R.W., Link G. Development and evaluation of the improved iron chelating agents EHPG, HBED and their dimethyl esters. Haematologia. 17:1984a;25-33.
43. Hershko C., Grady R.W., Link G. Phenolic ethylenediamine derivatives: a study of orally effective iron chelators. J Lab Clin Med. 103:1984b;337-346.
44. Hershko C., Konijn A.M., Nick H.P., Breuer W., Cabantchik Z.I., Link G. ICL670A: a new synthetic oral chelator: evaluation in hypertransfused rats with selective radioiron probes of hepatocellular and reticuloendothelial iron stores and in iron-loaded rat heart cells in culture. Blood. 97:2001;1115-1122.
45. Hider, R. C., Kontoghiorghes, G. J., & Silver, J. (1982). U.K. Patent GB-2118176.
46. Kawabata H., Yang R., Hirama T., Vuong P.T., Kawano S., Gombart A.F., Koeffler H.P. Molecular cloning of transferrin receptor 2. A new member of the transferrin receptor-like family. J Biol Chem. 274:1999;20826-20832.
47. Lee P., Mohammed N., Marshall L., Abeysinghe R.D., Hider R.C., Porter J.B., Singh S. Intravenous infusion pharmacokinetics of desferrioxamine in thalassaemic patients. Drug Metab Dispos. 21:1993;640-644.
48. L'Eplattenier F., Murase I., Martell A.E. Chelating tendencies of N, N′-di(2-hydroxybenzyl)ethylenediamine-N, N′-diacetic acid. J Am Chem Soc. 89:1967;837-841.
49. Lin M., Rippe R.A., Niemela O., Brittenham G., Tsukamoto H. Role of iron in NF-kappa B activation and cytokine gene expression by rat hepatic macrophages. Am J Physiol. 272:1997;G1355-G1364.
50. Liu Z.D., Hider R.C. Design of clinically useful iron(III)-selective chelators. Med Res Rev. 22:2002;26-64.
51. Nick H.P., Acklin P., Faller B. ICL670A: a new, potent, orally active iron chelator. Bergeron R., Badman D., Brittenham G. Iron Chelators: New Development Strategies. 2000;311-331 Saratoga Publishers, Ponte Vedra, FL.
52. Nicolas G., Bennoun M., Devaux I., Beaumont C., Grandchamp B., Kahn A., Vaulont S. Lack of hepcidin gene expression and severe tissue iron overload in upstream stimulatory factor 2 (USF2) knockout mice. Proc Natl Acad Sci U S A. 98:2001;8780-8785.
53. Nicolas G., Chauvet C., Viatte L., Danan J.L., Bigard X., Devaux I., Beaumont C., Kahn A., Vaulont S. The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammation. J Clin Invest. 110:2002;1037-1044.
54. Olivieri N.F., Brittenham G.M. Iron-chelating therapy and the treatment of thalassemia. Blood. 89:1997;739-761.
55. Olivieri N.F., Brittenham G.M., McLaren C.E., Templeton D.M., Cameron R.G., McClelland R.A., Burt A.D., Fleming K.A. Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major. N Engl J Med. 339:1998;417-423.
56. Olivieri N.F., Nathan D.G., MacMillan J.H., Wayne A.S., Liu P.P., McGee A., Martin M., Koren G., Cohen A.R. Survival in medically treated patients with homozygous beta-thalassemia. N Engl J Med. 331:1994;574-578.
57. Park C.H., Valore E.V., Waring A.J., Ganz T. Hepcidin, a urinary antimicrobial peptide synthesized in the liver. J Biol Chem. 276:2001;7806-7810.
58. Pascoe A., Kerlin P., Steadman C., Clouston A., Jones D., Powell L., Jazwinska E., Lynch S., Strong R. Spur cell anaemia and hepatic iron stores in patients with alcoholic liver disease undergoing orthotopic liver transplantation. Gut. 45:1999;301-305.
59. Piga A., Galanello R., Cappellini M.D., Forni G.-L., Opitz H., Ford J.M., Sechaud R., Mueller C., Donato G., Alberti D. Phase II study of oral chelator ICL670 in thalassaemia patients with transfusional iron overload: efficacy, safety, pharmacokinetics (PK) and pharmacodynamics (PD) after 6 months of therapy. Blood. 100:(Suppl 1):2002;2383. (Abstract).
60. Pigeon C., Ilyin G., Courselaud B., Leroyer P., Turlin B., Brissot P., Loreal O. A new mouse liver-specific gene, encoding a protein homologous to human antimicrobial peptide hepcidin, is overexpressed during iron overload. J Biol Chem. 276:2001;7811-7819.
61. Pippard M.J., Callender S.T., Finch C.A. Ferrioxamine excretion in iron-loaded man. Blood. 60:1982;288-294.
62. Porter J.B. Deferoxamine pharmacokinetics. Semin Hematol. 38:2001a;63-68.
63. Porter J.B. Practical management of iron overload. Br J Haematol. 115:2001b;239-252.
64. Porter J.B., Davis B.A. Monitoring chelation therapy to achieve optimal outcome in the treatment of thalassaemia. Best Pract Res Clin Haematol. 15:2002;329-368.
65. Porter J.B., Huehns E.R. The toxic effects of desferrioxamine. Baillieres Clin Haematol. 2:1989;459-474.
66. Powell L.W. Changing concepts in haemochromatosis. Postgrad Med J. 46:1970;200-209.
67. Prescrire International. Deferiprone: new preparation. Poorly assessed. Prescrire Int. 9:2000;131-135.
68. Raynard B., Balian A., Fallik D., Capron F., Bedossa P., Chaput J.C., Naveau S. Risk factors of fibrosis in alcohol-induced liver disease. Hepatology. 35:2002;635-638.
69. Richardson D.R. The controversial role of deferiprone in the treatment of thalassemia. J Lab Clin Med. 137:2001;324-329.
70. Roetto A., Papanikolaou G., Politou M., Alberti F., Girelli D., Christakis J., Loukopoulos D., Camaschella C. Mutant antimicrobial peptide hepcidin is associated with severe juvenile hemochromatosis. Nat Genet. 33:2003;21-22.
71. Sadrzadeh S.M., Nanji A.A., Price P.L. The oral iron chelator, 1,2-dimethyl-3-hydroxypyrid-4-one reduces hepatic-free iron, lipid peroxidation and fat accumulation in chronically ethanol-fed rats. J Pharmacol Exp Ther. 269:1994;632-636.
72. Samuni A.M., Afeworki M., Stein W., Yordanov A.T., DeGraff W., Krishna M.C., Mitchell J.B., Brechbiel M.W. Multifunctional antioxidant activity of HBED iron chelator. Free Radic Biol Med. 30:2001;170-177.
73. Sartori M., Andorno S., Rigamonti C., Boldorini R. Chronic hepatitis C treated with phlebotomy alone: biochemical and histological outcome. Dig Liver Dis. 33:2001;157-162.
74. Sephton-Smith R. Iron excretion in thalassaemia major after administration of chelating agents. Br Med J. 2:1962;1577-1580.
75. Sergejew T., Forgiarini P., Schnebli H.P. Chelator-induced iron excretion in iron-overloaded marmosets. Br J Haematol. 110:2000;985-992.
76. Shaw S., Jayatilleke E. The role of cellular oxidases and catalytic iron in the pathogenesis of ethanol-induced liver injury. Life Sci. 50:1992;2045-2052.
77. Suzuki Y., Saito H., Suzuki M., Hosoki Y., Sakurai S., Fujimoto Y., Kohgo Y. Up-regulation of transferrin receptor expression in hepatocytes by habitual alcohol drinking is implicated in hepatic iron overload in alcoholic liver disease. Alcohol Clin Exp Res. 26:(8 Suppl):2002;26S-31S.
78. Thuma P.E., Olivieri N.F., Mabeza G.F., Biemba G., Parry D., Zulu S., Fassos F.F., McClelland R.A., Koren G., Brittenham G.M., Gordeuk V.R. Assessment of the effect of the oral iron chelator deferiprone on asymptomatic Plasmodium falciparum parasitemia in humans. Am J Trop Med Hyg. 58:1998;358-364.
79. Tsukamoto H. Iron regulation of hepatic macrophage TNFalpha expression. Free Radic Biol Med. 32:2002;309-313.
80. Tsukamoto H., Horne W., Kamimura S., Niemela O., Parkkila S., Yla-Herttuala S., Brittenham G.M. Experimental liver cirrhosis induced by alcohol and iron. J Clin Invest. 96:1995;620-630.
81. Tsukamoto H., Lin M., Ohata M., Giulivi C., French S.W., Brittenham G. Iron primes hepatic macrophages for NF-kappaB activation in alcoholic liver injury. Am J Physiol. 277:1999;G1240-G1250.
82. Wanless I.R., Sweeney G., Dhillon A.P., Guido M., Piga A., Galanello R., Gamberini M.R., Schwartz E., Cohen A.R. Lack of progressive hepatic fibrosis during long-term therapy with deferiprone in subjects with transfusion-dependent beta-thalassemia. Blood. 100:2002;1566-1569.
83. Yano M., Hayashi H., Wakusawa S., Sanae F., Takikawa T., Shiono Y., Arao M., Ukai K., Ito H., Watanabe K., Yoshioka K. Long term effects of phlebotomy on biochemical and histological parameters of chronic hepatitis C. Am J Gastroenterol. 97:2002;133-137.
84. Zurlo M.G., De Stefano P., Borgna-Pignatti C., Di Palma A., Piga A., Melevendi C., Di Gregorio F., Buratini M.G., Terzoli S. Survival and causes of death in thalassaemia major. Lancet. 2:1989;27-30.